![]() | License: Creative Commons Attribution No Derivatives 4.0 PDF - Published Version (6MB) - Repository staff only |
- DOI to cite this document:
- 10.5283/epub.51539
Abstract
Treatment of advanced melanoma with combined immune checkpoint inhibitor (ICI) therapy is complicated in up to 50% of cases by immune-related adverse events (irAE) that commonly include hepatitis, colitis and skin reactions. We previously reported that pre-therapy expansion of cytomegalovirus (CMV)-reactive CD4+ effector memory T cells (TEM) predicts ICI-related hepatitis in a subset of patients ...

Owner only: item control page